Study summary

Immunotherapy around surgery helped more people with early TNBC stay alive

KEYNOTE-522 trial (pembrolizumab, final survival) · 1,174 people, phase 3 · Published September 2024, New England Journal of Medicine

86.6%alive at 5 years, vs 81.7% without pembrolizumab

What was tested

Pembrolizumab or placebo added to chemotherapy before surgery, then pembrolizumab or placebo after surgery, for stage II or III triple-negative breast cancer.

What they found

What it means

Confirms the KEYNOTE-522 regimen as the standard for stage II and III TNBC.

N Engl J Med, via PubMed ↗ Trial record NCT03036488 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.